Aclaris Therapeutics, Inc. (ACRS) Cash Flow Statement
Aclaris Therapeutics, Inc. (ACRS) generated -$62.1M of operating cash flow over the twelve months to 2026-06-30, spent $118000 on capital expenditure and had free cash flow of -$62.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ACRSAclaris Therapeutics, Inc.Follow ACRS — free
—
Price chart with a free account
- Market cap
- 552.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -54.7 | -100.8 | -96.4 | -38.6 | -52.1 | -67.6 | -78.3 | -20.1 | -47.1 | -62.1 | |
| Capital expenditure | 1.2 | 1.4 | 1.6 | 0.5 | 0.3 | 0.6 | 1.3 | 0.1 | 0.1 | -0.1 | |
| Free cash flow | -55.9 | -102.2 | -98.1 | -39.1 | -52.4 | -68.2 | -79.6 | -20.2 | -47.2 | -62.2 | |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | |
| Stock-based compensation | 14.4 | 20.1 | 16.2 | 11.2 | 14.1 | 15.0 | 20.5 | 10.9 | 12.4 | — |
USD millions · SEC XBRL
Aclaris Therapeutics, Inc. — questions
- What is Aclaris Therapeutics, Inc.'s operating cash flow?
- -$62.1M over the twelve months to 2026-06-30.
- How much does Aclaris Therapeutics, Inc. spend on capital expenditure?
- $118000 over the twelve months to 2026-06-30.
- What is Aclaris Therapeutics, Inc.'s free cash flow?
- -$62.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Aclaris Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.